Compare Divis Laboratories with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TTK HEALTHCARE - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TTK HEALTHCARE DIVIS LABORATORIES/
TTK HEALTHCARE
 
P/E (TTM) x 48.1 12.0 402.5% View Chart
P/BV x 12.9 1.7 741.2% View Chart
Dividend Yield % 0.5 0.9 53.4%  

Financials

 DIVIS LABORATORIES   TTK HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
TTK HEALTHCARE
Mar-19
DIVIS LABORATORIES/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,6391,215 134.9%   
Low Rs1,115610 182.8%   
Sales per share (Unadj.) Rs186.3444.4 41.9%  
Earnings per share (Unadj.) Rs51.017.2 295.5%  
Cash flow per share (Unadj.) Rs57.327.6 207.5%  
Dividends per share (Unadj.) Rs16.005.00 320.0%  
Dividend yield (eoy) %1.20.5 212.0%  
Book value per share (Unadj.) Rs261.8177.9 147.1%  
Shares outstanding (eoy) m265.4714.13 1,878.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.1 359.9%   
Avg P/E ratio x27.052.9 51.1%  
P/CF ratio (eoy) x24.033.0 72.7%  
Price / Book Value ratio x5.35.1 102.6%  
Dividend payout %31.429.0 108.3%   
Avg Mkt Cap Rs m365,59212,894 2,835.3%   
No. of employees `00011.82.3 512.4%   
Total wages/salary Rs m5,4231,307 414.9%   
Avg. sales/employee Rs Th4,175.12,715.7 153.7%   
Avg. wages/employee Rs Th457.7565.3 81.0%   
Avg. net profit/employee Rs Th1,141.8105.4 1,083.3%   
INCOME DATA
Net Sales Rs m49,4636,279 787.8%  
Other income Rs m1,55678 2,008.1%   
Total revenues Rs m51,0196,356 802.7%   
Gross profit Rs m18,718496 3,776.9%  
Depreciation Rs m1,689147 1,151.3%   
Interest Rs m3534 103.6%   
Profit before tax Rs m18,551393 4,725.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023149 3,373.6%   
Profit after tax Rs m13,527244 5,550.8%  
Gross profit margin %37.87.9 479.4%  
Effective tax rate %27.137.9 71.4%   
Net profit margin %27.33.9 704.6%  
BALANCE SHEET DATA
Current assets Rs m46,5012,717 1,711.3%   
Current liabilities Rs m8,4681,571 539.1%   
Net working cap to sales %76.918.3 421.1%  
Current ratio x5.51.7 317.5%  
Inventory Days Days13132 406.8%  
Debtors Days Days8647 184.0%  
Net fixed assets Rs m25,797991 2,603.1%   
Share capital Rs m531141 375.7%   
"Free" reserves Rs m68,9622,373 2,906.1%   
Net worth Rs m69,4932,514 2,763.9%   
Long term debt Rs m03 0.0%   
Total assets Rs m80,3834,158 1,933.2%  
Interest coverage x531.012.6 4,209.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.61.5 40.8%   
Return on assets %16.96.7 252.8%  
Return on equity %19.59.7 200.8%  
Return on capital %26.716.9 157.9%  
Exports to sales %03.6 0.0%   
Imports to sales %24.60.5 4,998.4%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs m12,18731 39,375.8%   
Fx inflow Rs m41,238225 18,311.5%   
Fx outflow Rs m12,40571 17,444.9%   
Net fx Rs m28,833154 18,711.5%   
CASH FLOW
From Operations Rs m9,543173 5,513.0%  
From Investments Rs m-6,85497 -7,102.6%  
From Financial Activity Rs m-2,459-307 800.3%  
Net Cashflow Rs m230-38 -609.0%  

Share Holding

Indian Promoters % 52.0 65.4 79.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 5.2 365.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 25.8 66.7%  
Shareholders   31,796 12,723 249.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 71.7% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 26, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ALEMBIC COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS